HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that CEO Howard Berman, Ph.D. will present at two upcoming healthcare conferences.
On September 26, 2024, Dr. Berman will participate in a panel discussion at Munsch Hardt’s 3rd Annual Texas Health Care Transactions Conference being held at the Houstonian Hotel in Houston, Texas. The panel is titled, “Affiliations with Hospital Systems: Exploring Paths to Collaboration and M&A,” and will begin at 1:15pm CT. This conference aims to connect more than 250 executives and thought leaders across today’s rapidly evolving health care industry, including top executives, practitioners, consultants, private equity investors, and venture capitalists. Investors can register here for the conference and gain access to this panel discussion.
On October 28, 2024, Dr. Berman and Dr. Stanley Appel, Chairman of Coya’s Scientific Advisory Board, will present at the inaugural Alzheimer’s Drug Discovery Foundation (ADDF) Summit: Advancements in Novel Therapeutics and Combination Therapy being held in Madrid, Spain at the Marriot Auditorium Hotel & Conference Center. At the summit, Drs. Berman and Appel will present data on COYA 302 and the role of Tregs in neurodegeneration. The summit is being held in alignment with the 2024 Clinical Trials on Alzheimer’s Disease (CTAD) conference also being held in Madrid at the same venue and being held from October 29 – November 1, 2024. The Company previously announced that results from a Gates Foundation and Alzheimer’s Association funded double-blind, placebo-controlled study in 38 patients with mild-to-moderate Alzheimer’s disease treated with low-dose interleukin-2 (LD IL-2) will be presented at CTAD by Dr. Alireza Faridar, Professor of Neurology at Houston Methodist and principal investigator, and will help guide further clinical development of COYA 302 for the treatment of Alzheimer’s disease.
The ADDF Summit is an invite-only event that convenes and connects Alzheimer’s experts across the field who are focused on developing cutting edge new treatments under the biology of biology framework with the end goal of advancing the field towards a combination therapy and precision medicine approach. This event is a full-day, interactive collaboration of scientists, academia, industry and government professionals, and other pioneers who are passionate about advancing the path to a cure and will consist of scientific presentations, panel discussions, and a keynote session.
In May 2024, the Company received a $5 million strategic equity investment from the ADDF to support the development of COYA 302 for the treatment of Frontotemporal Dementia (FTD). COYA 302’s combination therapeutic approach aligns with the ADDF’s belief in combination therapy being the future of treatment for Alzheimer’s disease and related dementias.
About Coya Therapeutics, Inc.
Headquartered in Houston, TX, Coya Therapeutics, Inc. (Nasdaq: COYA) is a clinical-stage biotechnology company developing proprietary treatments focused on the biology and potential therapeutic advantages of regulatory T cells (“Tregs”) to target systemic inflammation and neuroinflammation. Dysfunctional Tregs underlie numerous conditions, including neurodegenerative, metabolic, and autoimmune diseases, and this cellular dysfunction may lead to sustained inflammation and oxidative stress resulting in lack of homeostasis of the immune system.
Coya’s investigational product candidate pipeline leverages multiple therapeutic modalities aimed at restoring the anti-inflammatory and immunomodulatory functions of Tregs. Coya’s therapeutic platforms include Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.
COYA 302 – the Company’s lead biologic investigational product or “Pipeline in a Product”– is a proprietary combination of COYA 301 (Coya’s proprietary LD IL-2) and proprietary CTLA4-Ig fusion protein (in-licensed from Dr. Reddy’s Laboratories) for subcutaneous administration with a unique dual mechanism of action that is now being developed for the treatment of Amyotrophic Lateral Sclerosis, Frontotemporal Dementia, Parkinson’s Disease, and Alzheimer’s Disease. Its multi-targeted approach enhances the number and anti-inflammatory function of Tregs and simultaneously lowers the expression of activated microglia and the secretion of pro-inflammatory mediators. This synergistic mechanism may lead to the re-establishment of immune balance and amelioration of inflammation in a sustained and durable manner that may not be achieved by either low-dose IL-2 or CTLA4-Ig alone.
For more information about Coya, please visit www.coyatherapeutics.com
Forward-Looking Statements
This press release contains “forward-looking” statements that are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than statements of historical fact contained in this presentation, including information concerning our current and future financial performance, business plans and objectives, current and future clinical and preclinical development activities, timing and success of our ongoing and planned clinical trials and related data, the timing of announcements, updates and results of our clinical trials and related data, our ability to obtain and maintain regulatory approval, the potential therapeutic benefits and economic value of our product candidates, competitive position, industry environment and potential market opportunities. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” and similar expressions are intended to identify forward-looking statements.
Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors including, but not limited to, those related to risks associated with the impact of COVID-19; the success, cost and timing of our product candidate development activities and ongoing and planned clinical trials; our plans to develop and commercialize targeted therapeutics; the progress of patient enrollment and dosing in our preclinical or clinical trials; the ability of our product candidates to achieve applicable endpoints in the clinical trials; the safety profile of our product candidates; the potential for data from our clinical trials to support a marketing application, as well as the timing of these events; our ability to obtain funding for our operations; development and commercialization of our product candidates; the timing of and our ability to obtain and maintain regulatory approvals; the rate and degree of market acceptance and clinical utility of our product candidates; the size and growth potential of the markets for our product candidates, and our ability to serve those markets; our commercialization, marketing and manufacturing capabilities and strategy; future agreements with third parties in connection with the commercialization of our product candidates; our expectations regarding our ability to obtain and maintain intellectual property protection; our dependence on third party manufacturers; the success of competing therapies or products that are or may become available; our ability to attract and retain key scientific or management personnel; our ability to identify additional product candidates with significant commercial potential consistent with our commercial objectives; and our estimates regarding expenses, future revenue, capital requirements and needs for additional financing.
We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives, and financial needs. Moreover, we operate in a very competitive and rapidly changing environment, and new risks may emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed herein may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Although our management believes that the expectations reflected in our forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances described in the forward-looking statements will be achieved or occur. We undertake no obligation to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.